Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Clinical trial NCT02203825 · COMPLETED
Trial details
- NCT number
- NCT02203825
- Sponsor
- Celyad Oncology SA
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2018-03-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.